









Markets
/
Stocks
/
nasdaq-glto
/

Galecto Inc

GLTO

View Detailed Chart

3.395USD

+0.190+5.93%

Market hours （ET）Quotes delayed by 15 min

4.49MMarket Cap

LossP/E TTM



Galecto Inc

3.395

+0.190+5.93%

Overview Company Financials

Financials

Intraday

30m

Today

+5.93%

5 Days

-9.47%

1 Month

-4.10%

6 Months

-30.29%

Year to Date

-26.99%

1 Year

-74.08%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 1 analysts

HOLD

Current Rating

6.000

Target Price

87.21%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Galecto Inc

GLTO

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(7)

Neutral(2)

Buy(2)

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.124

Neutral

RSI(14)

38.878

Neutral

STOCH(KDJ)(9,3,3)

18.932

Sell

ATR(14)

0.328

Low Volatility

CCI(14)

-191.936

Sell

Williams %R

89.394

Oversold

TRIX(12,20)

0.227

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

3.435

Sell

MA10

3.576

Sell

MA20

3.546

Sell

MA50

3.389

Buy

MA100

3.292

Buy

MA200

4.412

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Galecto, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.

Ticker SymbolGLTO

CompanyGalecto Inc

CEODr. Hans T. Schambye, M.D., Ph.D.

Websitehttps://galecto.com/